Form 4: Edgewise Therapeutics CFO Exercises Stock Options
SEC Form 4
R. Michael Carruthers, CFO of Edgewise Therapeutics, exercised stock options and acquired 70,000 shares of common stock at $0.71 per share on October 11, 2024.
Summary
- On October 11, 2024, R. Michael Carruthers, the Chief Financial Officer of Edgewise Therapeutics, Inc., exercised stock options.
- This transaction involved the acquisition of 70,000 shares of common stock at a price of $0.71 per share.
- Following the transaction, Carruthers directly owns 76,904 shares of common stock.
- Carruthers also holds 127,122 stock options.
Sentiment
Score: 5
Explanation: Neutral sentiment as it reports a standard transaction related to executive compensation.
Industry Context
This is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 09/01/2024 | Date exercisable for stock options |
| 10/11/2024 | Date of transaction: CFO exercised stock options and acquired common stock. |
| 09/01/2030 | Expiration date for stock options. |
| 10/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.